Combination of anti-diabetic drug metformin and boswellic acid nanoparticles: A novel strategy for pancreatic cancer therapy

Journal of Biomedical Nanotechnology

Volumn 11, Issue 1, 2015, Pages 93-104

  Snima, K S ^a   Nair, Reshmi S ^a   Nair, Shantikumar V ^a   Kamath, C Ravindranath ^a   Lakshmanan, Vinoth Kumar ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Boswellic acid nanoparticles; Cancer therapy; Metformin; Pancreatic cancer; Synergism

Indexed keywords

CELL CULTURE; CELL DEATH; CELL MEMBRANES; CELL PROLIFERATION; CHEMOTHERAPY; DISEASES; MAGNESIUM PRINTING PLATES; MITOCHONDRIA; NANOPARTICLES; ONCOLOGY;

BOSWELLIC ACIDS; CANCER THERAPY; METFORMINS; PANCREATIC CANCERS; SYNERGISM;

RADIOTHERAPY;

BOSWELLIC ACID; METFORMIN; NANOPARTICLE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; NANOCAPSULE; TRITERPENE;

APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER THERAPY; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG POTENTIATION; FLOW CYTOMETRY; HEMOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOCHONDRIAL MEMBRANE POTENTIAL; PANCREAS CANCER; PANCREAS CELL; PANCREATIC CANCER CELL LINE; CHEMISTRY; DIFFUSION; DOSE RESPONSE; DRUG EFFECTS; PANCREATIC NEOPLASMS; PARTICLE SIZE; PATHOLOGY; ULTRASTRUCTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NANOCAPSULES; PANCREATIC NEOPLASMS; PARTICLE SIZE; TRITERPENES;

EID: 84918560373     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.1877     Document Type: Article

References (44)

1. R. Siegel and A. Jemal, Cancer Facts and Figures 2013, American Cancer Society, Atlanta (2013).
2. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, and M. J. Thun, Cancer statistics. CA. A Cancer Journal for clinicians 58, 71 (2008).
3. S. Yohe, Y. Masahiro, K. Jun-Ichiro, K. Yoshikatsu, and M. Yasuhiro, Antitumour activity of NK012,SN-38 incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour. European Journal of Cancer 46, 650 (2010).
4. A. L. Warshaw and C. Fernandez-del, Pancreatic carcinoma. The New Engalnad Journal of Medicine 326, 455 (1992).
5. M. Gaviraghi, P. Tunici, S. Valensin, M. Rossi, and C. Giordano, Pancreatic cancer spheres are more than just aggregates of stem marker positive cells. Bioscience Reports 31, 77 (2011).
6. H. Riediger, T. Keck, U. Wellner, A. Zur Hausen, U. Adam, U. T. Hopt, and F. Makowiec, The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. Journal of Gastrointestinal Surgery 13, 1337 (2009).
7. J. Permert, I. Ihse, L. Jorfeldt, H. von Schenck, H. J. Arnqvist, and J. Larsson, Pancreatic cancer is associated with impaired glucose metabolism. European Journal of Surgery 159, 101 (1993).
8. S. S. Schwarts, A. Zeidler, A. R. Moossa, S. F. Kuku, and A. H. Rubenstein, A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Digestive Diseases and Sciences 23, 1107 (1978).
9. R. J. Shaw, K. A. Lamia, D. Vasquez, S. H. Koo, N. Bardeesy, and R. A. Depinho, The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642 (2005).
10. D. Rachel, C. Angela, and S. Pesach, Glucose tolerance status and 20 year cancer incidence. The Israel Medical Association Journal 9, 592 (2007).
11. L. Gullo, R. Pezzilli, and A. M. Morselli, Diabetes and the risk of pancreatic cancer: Italian pancreatic cancer study group. New England Journal of Medicine 331, 84 (1994).
12. J. Everhart and D. Wright, Diabetes mellitus as a risk factor for pancreatic cancer. JAMA 273, 1605 (1995).
13. S. M. Gapstur, P. H. Gann, W. Lowe, K. K. Liu, L. Colangelo, and Dyer, A Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 283, 2558 (2000).
14. E. E. Calle, T. K. Murphy, C. Rodriguez, M. J. Thun, and C. W. Heath, Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 9, 403 (1998).
15. Y. H. Feng, G. Velazquez-Torres, C. Gully, J. Chen, M. H. Lee, and S. C. Yeung, The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J. Cell Mol. Med. 15, 825 (2011).
16. S. M. Hadad, S. Fleming, and A. M. Thompson, Targeting AMPK: A new therapeutic opportunity in breast cancer. Crit. Rev. Oncol. Hematol. 67, 7 (2008).
17. K. H. Rabbie, Z. Chunxiao, M. M. Kimberly, S. Li, Z. Yan, A. G. Paola, and L. B. Victoria, Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecologic Oncology 125, 458 (2012).
18. P. S. Heloisa, N. Yang, K. Krisztina, S. S. James, and R. Enrique, Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. Plos One 8, e57289 (2013).
19. B. Bin, W. Zhiwei, A. Shadan, A. Aamir, S. Asfar, H. S. Sanila, B. Sanjeev, K. Dejuan, L. Yiwei, T. Shivam, and H. S. Fazlul, Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res. 5, 355 (2012).
20. G. C. Jagetia, M. S. Baliga, K. J. Malagi, and M. S. Kamath, The evaluation of the radioprotective effect of Triphala (an Ayurvedic rejuvenating drug) in the mice exposed to gamma-radiation. Phytomedicine 9, 99 (2002).
21. H. R. Kim, M. S. Kim, D. Y. Kwon, S. W. Chae, and H. J. Chae, Bosellia serrata induced apoptosis is related with ER stress and calcium release. Genes and Nutrition 2, 371 (2008).
22. S. Treadway, An ayurvedic herbal approach to a healthy liver. Clinical Nutritional Insights 6, 1 (1998).
23. H. Abram and P. Jonathan, Successful treatment of schizophrenia requires optimal daily doses of vitamin B3. Alternative Medicine Review 13, 2 (2008).
24. H. P. Ammon, Modulation of the immune system by Boswellia serrata extracts and boswellic acids. Phytomedicine 17, 862 (2010).
25. T. Glaser, S. Winter, P. Groscurth, H. Safayhi, E. R. Sailer, H. P. Ammon, M. Schabet, and M. Weller, Boswellic acids and malignant glioma: Induction of apoptosis but no modulation of drug sensitivity. Br. J. Cancer. 80, 756 (1999).
26. J. J. Liu, A. Nilsson, S. Oredsson, V. Badmaev, and R. D. Duan. Keto- and acetylketo-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via a caspase-8 dependent pathway. Int. J. Mol. Med. 10, 501 (2002).
27. J. J. Liu, B. Huang, and S. C. Hooi, Acetyl-keto-beta-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells. Br. J. Pharmacol. 148, 1099 (2006).
28. J. J. Liu and R. D. Duan, LY294002 enhances boswellic acid-induced apoptosis in colon cancer cells. Anticancer. Res. 29, 2987 (2009).
29. M. T. Huang, V. Badmaev, Y. Ding, Y. Liu, J. G. Xie, and C. T. Ho, Anti-tumor and anti-carcinogenic activities of triterpenoid, betaboswellic acid. Biofactors 13, 225 (2000).
30. Y. Shao, C. T. Ho, C. K. Chin, V. Badmaev, W. Ma, and M. T. Huang, Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. Planta Med. 64, 328 (1998).
31. R. F. Hoernlein, T. Orlikowsky, C. Zehrer, D. Niethammer, E. R. Sailer, T. Simmet, G. E. Dannecker, and H. P. Ammon, Acetyl- 11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRFCEM cells and inhibits topoisomerase I. J. Pharmacol. Exp. Ther. 288, 613 (1999).
32. L. Xia, D. Chen, R. Han, Q. Fang, S. Waxman, and Y. Jing. Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells. Mol. Cancer Ther. 4, 381 (2005).
33. S. Bhushan, A. Kumar, F. Malik, S. S. Andotra, V. K. Sethi, I. P. Kaur, S. C. Taneja, G. N. Qazi, and J. Singh, A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells. Apoptosis 12, 1911 (2007).
34. W. Zhao, F. Entschladen, H. Liu, B. Niggemann, Q. Fang, K. S. Zaenker, and R. Han, Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells. Cancer Detect Prev. 27, 67 (2003).
35. T. Syrovets, J. E. Gschwend, B. Buchele, Y. Laumonnier, W. Zugmaier, F. Genze, and T. Simmet, Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J. Biol. Chem. 280, 6170 (2005).
36. P. Byoungduck, P. Sahdeo, Y. Vivek, S. Bokyung, and B. A. Bharat, Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets. Plos one 6, 1 (2011).
37. X. Ni, M. M. Suhail, Q. Yang, A. Cao, K. M. Fung, R. G. Postier, C. Woolley, G. Young, J. Zhang, and H. K. Lin, Frankincense essential oil prepared from hydrodistillation of Boswellia sacra gum resins induces human pancreatic cancer cell death in cultures and in a xenograft murine model. BMC Complement Altern Med. 12, 235 (2012).
38. U. Saji, K. S. Snima, M. Annapoorna, K. C. Ravindranath, S. V. Nair, and K. L. Vinoth, Novel Boswellic acid Nanoparticle induce cell death in prostate cancer cells. Journal of Natural products 5, 100 (2012).
39. N. C. Devika, U. Saji, K. S. Snima, A. K. K. Unni, K. C. Ravindranath, S. V. Nair, and K. L. Vinoth, Therapeutic properties of boswellic acid nanoparticles in prostate tumor-bearing BALB/c mice model. Nano Pharmaceutics and Drug Delivery 1, 30 (2013).
40. E. Finkel, The mitochondrion: Is it central to apoptosis? Science 292, 624 (2001).
41. H. Dorian, M. Marco, L. Cristina, and C. S. Charles, The effects of carboxylic acids on the aqueous dispersion and electrophoretic deposition of ZrO2. J. Eur. Ceram. Soc. 32, 235 (2012).
42. M. Reers, S. T. Smiley, C. Mottola-Hartshorn, A. Chen, M. Lin, and L. B. Chen, Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol 260, 406 (1995).
43. A. Cossariza, M. Baccarani-Contri, G. Kalashinikova, and C. Franceschi, A method for the cytofluorimetric analysis of mitochondrial membrane potential using J-aggregate forming cationic 5,5,6,6tetrachloro-1.1,3,3tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem. Biophs. Res. Comm. 197, 40 (1993).
44. S. S. James, K. Krisztina, K. K. Robert, H. Y. Steven, and R. Enrique, Synergistic inhibition of pancreatic cancer cell proliferation by metformin and rapamycin: Identification of a novel combinatorial drug strategy. Gastroenterology 142, S-129 (2012).